Stone House Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Stone House Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105	Buy	+7	New	+$97	﹤0.01%	1286

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Stone House Investment Management's CRVS Position: Q2 2026 in Review

Stone House Investment Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 7 shares worth $105. The stake represents ﹤0.01% of the portfolio and ranks #1286 among its holdings.

173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Stone House Investment Management held 7 shares of Corvus Pharmaceuticals worth $105 as of Q2 2026.
Corvus Pharmaceuticals was a new Stone House Investment Management position in Q2 2026.
Corvus Pharmaceuticals made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1286 holding.
173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.